Cargando…

Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction

Aim: A direct oral anti-coagulant, FXa inhibitor, has been applied to the clinical treatment of myocardial infarction (MI). Experimental studies in mice indicated that FXa inhibitors reduced atherosclerosis and prevented cardiac dysfunction after coronary ligation. These studies suggested that prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingyi, Nishida, Makoto, Inui, Hiroyasu, Chang, Jiuyang, Zhu, Yinghong, Kanno, Kotaro, Matsuda, Hibiki, Sairyo, Masami, Okada, Takeshi, Nakaoka, Hajime, Ohama, Tohru, Masuda, Daisaku, Koseki, Masahiro, Yamashita, Shizuya, Sakata, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800390/
https://www.ncbi.nlm.nih.gov/pubmed/30867376
http://dx.doi.org/10.5551/jat.48405
_version_ 1783460431614967808
author Liu, Jingyi
Nishida, Makoto
Inui, Hiroyasu
Chang, Jiuyang
Zhu, Yinghong
Kanno, Kotaro
Matsuda, Hibiki
Sairyo, Masami
Okada, Takeshi
Nakaoka, Hajime
Ohama, Tohru
Masuda, Daisaku
Koseki, Masahiro
Yamashita, Shizuya
Sakata, Yasushi
author_facet Liu, Jingyi
Nishida, Makoto
Inui, Hiroyasu
Chang, Jiuyang
Zhu, Yinghong
Kanno, Kotaro
Matsuda, Hibiki
Sairyo, Masami
Okada, Takeshi
Nakaoka, Hajime
Ohama, Tohru
Masuda, Daisaku
Koseki, Masahiro
Yamashita, Shizuya
Sakata, Yasushi
author_sort Liu, Jingyi
collection PubMed
description Aim: A direct oral anti-coagulant, FXa inhibitor, has been applied to the clinical treatment of myocardial infarction (MI). Experimental studies in mice indicated that FXa inhibitors reduced atherosclerosis and prevented cardiac dysfunction after coronary ligation. These studies suggested that protease-activated receptor (PAR) 2, a major receptor of activated FX, may play an important role in atherosclerosis and cardiac remodeling. Methods: The effects of a FXa inhibitor, rivaroxaban, were investigated in a new murine model of ischemic cardiomyopathy (ICM) using SR-BI KO/ApoeR61(h/h) mice (Hypo E mice) that developed MI by high-fat diet loading. Results: Hypo E mice were fed rivaroxaban-containing (n = 49) or control chow diets (n = 126) after the induction of MI. The survival curve of the rivaroxaban-treated group 2 weeks after the induction of MI was improved significantly as compared with the non-treatment group (survival rate: 75.5% vs. 47.4%, respectively, p = 0.0012). Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure. Histological analyses revealed that rivaroxaban reduced aortic atherosclerosis and coronary occlusion, and markedly attenuated cardiac fibrosis. Rivaroxaban treatment decreased cardiac PAR2 levels and pro-inflammatory genes. In vitro, rivaroxaban application demonstrated the increase of cell viability against hypoxia in cardiac myocytes and the reduction of hypoxia-induced inflammation and fibrosis-related molecules in cardiac fibroblasts. The effects of the PAR2 antagonist against hypoxia-induced inflammation were comparable to rivaroxaban in cardiac fibroblasts. Conclusions: Rivaroxaban treatment just after MI in Hypo E mice prevented the progression of ICM by attenuating cardiac remodeling, partially through the suppression of the PAR2-mediated inflammatory pathway.
format Online
Article
Text
id pubmed-6800390
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-68003902019-10-25 Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction Liu, Jingyi Nishida, Makoto Inui, Hiroyasu Chang, Jiuyang Zhu, Yinghong Kanno, Kotaro Matsuda, Hibiki Sairyo, Masami Okada, Takeshi Nakaoka, Hajime Ohama, Tohru Masuda, Daisaku Koseki, Masahiro Yamashita, Shizuya Sakata, Yasushi J Atheroscler Thromb Original Article Aim: A direct oral anti-coagulant, FXa inhibitor, has been applied to the clinical treatment of myocardial infarction (MI). Experimental studies in mice indicated that FXa inhibitors reduced atherosclerosis and prevented cardiac dysfunction after coronary ligation. These studies suggested that protease-activated receptor (PAR) 2, a major receptor of activated FX, may play an important role in atherosclerosis and cardiac remodeling. Methods: The effects of a FXa inhibitor, rivaroxaban, were investigated in a new murine model of ischemic cardiomyopathy (ICM) using SR-BI KO/ApoeR61(h/h) mice (Hypo E mice) that developed MI by high-fat diet loading. Results: Hypo E mice were fed rivaroxaban-containing (n = 49) or control chow diets (n = 126) after the induction of MI. The survival curve of the rivaroxaban-treated group 2 weeks after the induction of MI was improved significantly as compared with the non-treatment group (survival rate: 75.5% vs. 47.4%, respectively, p = 0.0012). Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure. Histological analyses revealed that rivaroxaban reduced aortic atherosclerosis and coronary occlusion, and markedly attenuated cardiac fibrosis. Rivaroxaban treatment decreased cardiac PAR2 levels and pro-inflammatory genes. In vitro, rivaroxaban application demonstrated the increase of cell viability against hypoxia in cardiac myocytes and the reduction of hypoxia-induced inflammation and fibrosis-related molecules in cardiac fibroblasts. The effects of the PAR2 antagonist against hypoxia-induced inflammation were comparable to rivaroxaban in cardiac fibroblasts. Conclusions: Rivaroxaban treatment just after MI in Hypo E mice prevented the progression of ICM by attenuating cardiac remodeling, partially through the suppression of the PAR2-mediated inflammatory pathway. Japan Atherosclerosis Society 2019-10-01 /pmc/articles/PMC6800390/ /pubmed/30867376 http://dx.doi.org/10.5551/jat.48405 Text en 2019 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Liu, Jingyi
Nishida, Makoto
Inui, Hiroyasu
Chang, Jiuyang
Zhu, Yinghong
Kanno, Kotaro
Matsuda, Hibiki
Sairyo, Masami
Okada, Takeshi
Nakaoka, Hajime
Ohama, Tohru
Masuda, Daisaku
Koseki, Masahiro
Yamashita, Shizuya
Sakata, Yasushi
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction
title Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction
title_full Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction
title_fullStr Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction
title_full_unstemmed Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction
title_short Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction
title_sort rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800390/
https://www.ncbi.nlm.nih.gov/pubmed/30867376
http://dx.doi.org/10.5551/jat.48405
work_keys_str_mv AT liujingyi rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT nishidamakoto rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT inuihiroyasu rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT changjiuyang rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT zhuyinghong rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT kannokotaro rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT matsudahibiki rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT sairyomasami rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT okadatakeshi rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT nakaokahajime rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT ohamatohru rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT masudadaisaku rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT kosekimasahiro rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT yamashitashizuya rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction
AT sakatayasushi rivaroxabansuppressestheprogressionofischemiccardiomyopathyinamurinemodelofdietinducedmyocardialinfarction